Victory Capital Management
FATE icon

Victory Capital Management’s Fate Therapeutics FATE Stock Holding History

Victory Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.1K Sell
12,595
-33
-0.3% -$40 ﹤0.01% 2386
2025
Q4 		$12.4K Buy
12,628
+28
+0.2% +$34 ﹤0.01% 2405
2025
Q3 		$15.9K Sell
12,600
-170
-1% -$183 ﹤0.01% 2406
2025
Q2 		$14.3K Buy
12,770
+898
+8% +$1.04K ﹤0.01% 2459
2025
Q1 		$9.38K Sell
11,872
-245
-2% -$300 ﹤0.01% 2457
2024
Q4 		$20K Buy
12,117
+39
+0.3% +$98 ﹤0.01% 2443
2024
Q3 		$42.3K Sell
12,078
-91,941
-88% -$358K ﹤0.01% 2401
2024
Q2 		$341K Sell
104,019
-79,931
-43% -$350K ﹤0.01% 2071
2024
Q1 		$1.35M Buy
183,950
+171,446
+1,371% +$1.06M ﹤0.01% 1599
2023
Q4 		$46.8K Buy
12,504
+2,322
+23% +$5.48K ﹤0.01% 2444
2023
Q3 		$21.6K Buy
+10,182
New +$33.7K ﹤0.01% 2442
2023
Q2 		– Sell
-10,228
Closed -$58.3K – 2546
2023
Q1 		$58.3K Sell
10,228
-749,574
-99% -$4.52M ﹤0.01% 2430
2022
Q4 		$7.67M Sell
759,802
-221,137
-23% -$4.15M 0.01% 1103
2022
Q3 		$22M Sell
980,939
-92,854
-9% -$2.68M 0.03% 762
2022
Q2 		$26.6M Buy
1,073,793
+51,086
+5% +$1.41M 0.03% 706
2022
Q1 		$39.5M Buy
1,022,707
+67,395
+7% +$2.61M 0.04% 618
2021
Q4 		$55.9M Buy
955,312
+43,132
+5% +$2.44M 0.05% 522
2021
Q3 		$54.1M Sell
912,180
-403,421
-31% -$31.6M 0.05% 517
2021
Q2 		$114M Sell
1,315,601
-11,344
-0.9% -$914K 0.11% 234
2021
Q1 		$109M Sell
1,326,945
-424,510
-24% -$40.7M 0.11% 232
2020
Q4 		$159M Sell
1,751,455
-682,968
-28% -$42.4M 0.18% 135
2020
Q3 		$97.3M Sell
2,434,423
-128,848
-5% -$4.5M 0.12% 210
2020
Q2 		$87.9M Sell
2,563,271
-4,385,465
-63% -$131M 0.12% 236
2020
Q1 		$154M Buy
6,948,736
+2,719,582
+64% +$68.8M 0.13% 214
2019
Q4 		$82.8M Buy
4,229,154
+571,834
+16% +$9.08M 0.1% 288
2019
Q3 		$56.8M Buy
3,657,320
+729,390
+25% +$14M 0.07% 405
2019
Q2 		$59.4M Buy
2,927,930
+953,756
+48% +$17.2M 0.12% 248
2019
Q1 		$34.7M Buy
1,974,174
+655,314
+50% +$10.3M 0.08% 396
2018
Q4 		$16.9M Buy
1,318,860
+791,540
+150% +$11M 0.04% 588
2018
Q3 		$8.59M Buy
527,320
+12,840
+2% +$152K 0.02% 785
2018
Q2 		$5.83M Sell
514,480
-60,410
-11% -$665K 0.01% 822
2018
Q1 		$5.61M Buy
574,890
+240,210
+72% +$2.3M 0.01% 821
2017
Q4 		$2.04M Buy
334,680
+241,890
+261% +$1.08M ﹤0.01% 1023
2017
Q3 		$367K Buy
+92,790
New +$316K ﹤0.01% 1352

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Victory Capital Management's FATE Position: Q1 2026 in Review

Victory Capital Management reduced its Fate Therapeutics (FATE) stake by 0.26% in Q1 2026, selling an estimated $40 and leaving 12,595 shares worth $15.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2386.

Victory Capital Management first reported a position in FATE in Q3 2017 and has held it in 34 quarters since. The position peaked at $159M in Q4 2020. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Victory Capital Management held 12,595 shares of Fate Therapeutics worth $15.1K as of Q1 2026.
  • Victory Capital Management sold 33 Fate Therapeutics shares in Q1 2026, an estimated $40.
  • Fate Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #2386 holding.
  • Victory Capital Management first reported a position in Fate Therapeutics in Q3 2017 and has held it in 34 quarters since.
  • Victory Capital Management's Fate Therapeutics position peaked at $159M in Q4 2020.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.